European Regulators Recommend Revoking Tavneos Marketing Authorization

The European Medicines Agency's committee has advised withdrawing the marketing authorization for Tavneos, a drug used for rare inflammatory conditions. This recommendation stems from concerns regarding the integrity of data from the primary study that supported its initial approval. Regulators concluded that the drug's benefits are no longer sufficiently proven to outweigh its potential risks.